期刊文献+

大疱性类天疱疮患者并发糖尿病情况分析 被引量:3

Retrospective Analysis of the Prevalence of Diabetes in Bullous Pemphigoid Patients
下载PDF
导出
摘要 目的了解系统糖皮质激素治疗前后大疱性类天疱疮(BP)患者糖尿病患病情况及临床特点。方法回顾性分析2005年6月-2016年2月北京医院皮肤科和北京大学第三医院皮肤科收治的45例BP患者的临床资料,并与同期90例接受系统性应用糖皮质激素治疗的湿疹患者进行对照分析。结果系统性应用糖皮质激素治疗前,BP组与湿疹组诊断为2型糖尿病者与非2型糖尿病者的性别构成和年龄组成及2型糖尿病患病比例的差异均无统计学意义(P均>0.05)。系统性应用糖皮质激素治疗8周后,BP组诊断为2型糖尿病者平均年龄较非糖尿病者大(P<0.05),性别差异无统计学意义(P>0.05),且BP组患糖皮质激素诱导性糖尿病(GC-DM)比例较湿疹组高(P<0.05),BP组和湿疹组患GC-DM者均较未患GC-DM者的年龄大(P<0.05)。有代谢综合征病史的BP患者较无该病史者更易发生GC-DM(P<0.05)。结论 BP患者较湿疹患者更易发生GC-DM,且年龄越大的BP患者和既往有代谢综合症病史的BP患者更易发生GC-DM。 Objective To investigate the prevalence of diabetes in patients with bullous pemphigoid(BP)treated with glucocorticoids(GC).Methods A retrospective analysis was performed in 45 BP patients and 90 cases of eczema treated with systemic GC at Beijing Hospital and No.3 Hospital of Peking University from June 2005 to February 2016.Results Before systemic GC treatment, BP and eczema patients were similar with respect to the morbidity of type 2 diabetes in gender and age.After 8-week treatment, both BP and eczema patients with type 2 diabetes were older than those without type 2 diabetes(P〈0.05); Gender did not affect the development of type 2 diabetes associated with GC treatment in BP patients; More BP patients developed type 2 diabetes in comparison with eczema patients; BP patients with metabolic syndrome(MS)were more susceptible to develop type 2 diabetes than those without MS(P〈0.05).Conclusion In comparison with eczema patients, BP patients, particularly the older and those with MS, are more likely to suffer from GC- type 2 diabetes.
出处 《中国皮肤性病学杂志》 CSCD 北大核心 2017年第5期501-504,共4页 The Chinese Journal of Dermatovenereology
关键词 大疱性类天疱疮 2型糖尿病 糖皮质激素 激素诱导性糖尿病 代谢综合征 湿疹 Bullous pemphigoid Type 2 diabetes Glucocorticoid therapy Glucocorticoid-induced diabetes melhtus Metabolic syndrome Eczema
  • 相关文献

参考文献4

二级参考文献31

  • 1宋秀霞 ,纪立农 .国际糖尿病联盟代谢综合征全球共识定义[J].中华糖尿病杂志(1006-6187),2005,13(3):178-180. 被引量:610
  • 2杨文英.糖尿病和糖尿病前期的诊断[J].中华内分泌代谢杂志,2005,21(4):401-404. 被引量:122
  • 3Alberti KGMM,Eckel RH,Grundy SM,et al.Harmonizing the metabolic syndrome:a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart,Lung,and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.Circulation,2009,120:1640-1645.
  • 4Wisse BE.The inflammatory syndrome:the role of adipose tissue cytokines in metabolic disorders linked to obesity.J Am Soc Nephrol,2004,15(11):2792-2800.
  • 5Kadowaki T,Yamauchi T.Adiponectin and adiponectin receptors.Endocr Rev,2005,26(3):439-451.
  • 6Herman WH,Hoerger TJ,Brandle M,et al.The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.Ann Intern Med,2005,142:323-332.
  • 7Tota-Maharaj R,Defilippis AP,Blumenthal RS,et al.A practical approach to the metabolic syndrome:review of current concepts and management.Curr Opin Cardiol,2010,25:502-512.
  • 8Li G,Zhang P,Wang J,et al.The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study:a 20-year follow-up study.Lancet,2008,371:1783-1789.
  • 9Knowler WC,Barrett-Connor E,Fowler SE,et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med,2002,346(6):393-403.
  • 10Ha Y, Lee KH, Jung S, et al. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treatedwith high-dose glueoeorticoid therapy [J]. Lupus, 2011, 20( 10): 1027-1034.

共引文献61

同被引文献28

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部